Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
November 21, 2023 08:01 ET
|
Silo Pharma, Inc.
MedSpray’s patented nose-to-brain intranasal technology selected for SPC-15 drug delivery Exclusivity covers multiple indications including anxiety disorders, Alzheimer’s disease, and anorexia ...
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
November 08, 2023 08:11 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
October 16, 2023 08:11 ET
|
Silo Pharma, Inc.
Human tissue study assessed SPU-21’s efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a...
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
October 11, 2023 08:35 ET
|
Silo Pharma, Inc.
Study to test effectiveness of Instructional System Designs (ISD) model for Intranasal SPC-15 ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the...
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
September 20, 2023 08:28 ET
|
Silo Pharma, Inc.
Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
September 12, 2023 08:50 ET
|
Silo Pharma, Inc.
Investigational New Drug (IND) submission to FDA on target for Q1 2024 SPC-15, is a novel Serotonin 4 receptor agonist against stress, developed in conjunction with Columbia University ENGLEWOOD...
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
August 10, 2023 08:50 ET
|
Silo Pharma, Inc.
Clarivate will monitor, manage, and maintain Company’s expanding IP portfolio ENGLEWOOD CLIFFS, NJ, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a...
Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
August 08, 2023 08:30 ET
|
Silo Pharma, Inc.
Study data to determine potential delivery partners ENGLEWOOD CLIFFS, NJ, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical...
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
June 21, 2023 09:00 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, June 21, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
June 13, 2023 08:05 ET
|
Silo Pharma, Inc.
Initial indications are fibromyalgia and chronic pain ENGLEWOOD CLIFFS, NJ, June 13, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage...